Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization

J Allergy Clin Immunol. 2019 Nov;144(5):1320-1326.e1. doi: 10.1016/j.jaci.2019.07.030. Epub 2019 Sep 4.

Abstract

Background: Peanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergic children. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment.

Objective: We sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanut allergy.

Methods: Children with peanut allergy aged 1 to 11 years underwent extended maintenance SLIT with 2 mg/d peanut protein for up to 5 years. Subjects with peanut skin test wheals of less than 5 mm and peanut-specific IgE levels of less than 15 kU/L were allowed to discontinue therapy early. Desensitization was assessed through a double-blind, placebo-controlled food challenge (DBPCFC) with up to 5000 mg of peanut protein after completion of SLIT dosing. Sustained unresponsiveness was further assessed by using identical DBPCFCs after 2 to 4 weeks without peanut exposure.

Results: Thirty-seven of 48 subjects completed 3 to 5 years of peanut SLIT, with 67% (32/48) successfully consuming 750 mg or more during DBPCFCs. Furthermore, 25% (12/48) passed the 5000-mg DBPCFC without clinical symptoms, with 10 of these 12 demonstrating sustained unresponsiveness after 2 to 4 weeks. Side effects were reported with 4.8% of doses, with transient oropharyngeal itching reported most commonly. Side effects requiring antihistamine treatment were uncommon (0.21%), and no epinephrine was administered. Peanut skin test wheals, peanut-specific IgE levels, and basophil activation decreased significantly, and peanut-specific IgG4 levels increased significantly after peanut SLIT.

Conclusion: Extended-therapy peanut SLIT provided clinically meaningful desensitization in the majority of children with peanut allergy that was balanced with ease of administration and a favorable safety profile.

Keywords: Peanut allergy; food allergy treatments; food desensitization; food immunotherapy; sublingual immunotherapy; sustained unresponsiveness.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allergens / immunology
  • Arachis / immunology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immune Tolerance
  • Immunization
  • Immunoglobulin E / metabolism
  • Infant
  • Male
  • Peanut Hypersensitivity / immunology
  • Peanut Hypersensitivity / therapy*
  • Sublingual Immunotherapy / methods*
  • Time Factors*
  • Treatment Outcome

Substances

  • Allergens
  • Immunoglobulin E